Abstract
At the end of the twentieth century, there were great expectations that neuroscience discoveries catalyzed by the Decade of the Brain would result in enhanced clinical practices for treatment and prevention of Attention-Deficit/Hyperactivity Disorder (ADHD) or Hyperkinetic Disorder (HKD), which were summarized by an international collaborative group of child psychologists and psychiatrists (Swanson JM, Sergeant J, Taylor E, Sonuga-Barke EJS, Jensen PS, Cantwell DP: Lancet 351:429–433, 1998). Based on five topics (diagnosis, epidemiology, treatment, prognosis, and pathophysiology), we suggested that “brain imaging studies implicate the frontal basal-ganglia neural networks,” “molecular genetic studies implicate the dopamine pathways that modulate and integrate neural activity of these networks,” and “neuroanatomical and biochemical abnormalities provide firm ground to build an understanding of the biological bases of ADHD/HKD.” Almost 20 years later, the collaborative group was reconvened (Swanson JM, Sergeant JA, Taylor EA, Sonuga-Barke EJS, Jensen PS, Castellanos FX: Chapter 142: attention deficit hyperactivity disorder. In: Pfaff DW, Volkow ND (eds) Neuroscience in the 21st century. Springer, New York, 2016) and prepared a chapter for the second edition of Neuroscience in the twenty-first Century. During the beginning of the twenty-first century, we noted progress was made, but problems emerged that muted the previous hopes and expectations. We concluded “the underlying pathophysiology of ADHD is much more complex than suggested by research from the twentieth century,” “ADHD is not a unitary condition and instead is a final common pathway of many underlying biologic and environmental factors,” and “research should clarify these factors and enable the refinement of available intervention and the development of new interventions for ADHD across the life span.” For this revision, we reconstituted the group to provide another update based on the same five topics that were addressed previously. Brief reviews are provided to summarize the (a) revisions to the official diagnostic criteria that define essential features of the modern disorder, (b) estimates of the administrative prevalence in different countries of the recognized disorder, (c) trends in use of stimulant and non-stimulant medications for treatment of the symptomatic disorder, (d) expectations of the course of the neurodevelopmental disorder, and (e) speculations about the biological and environmental causes of the complex disorder.
Similar content being viewed by others
References
Ahmed R, Aslani P (2013) An update on medication adherence and persistence in children. Expert Rev Pharmacoecon Outcome Res 13:791–815
Aldao A, Gee DG, De Los Reyes A, Seager I (2016) Emotion regulation as a transdiagnostic factor in the development of internalizing and externalizing psychopathology: current and future directions. Dev Psychopathol 28:927–946
Alexander LM, Salum GA, Swanson JM, Milham MP (2020) Measuring strengths and weaknesses in dimensional psychiatry. J Child Psychol Psychiatry 61:40–50
American Psychiatric Association (1952) DSM. American Psychiatric Association, Washington, DC
American Psychiatric Association (1968) DSM-II. American Psychiatric Association, Washington, DC
American Psychiatric Association (1980) DSM-III. American Psychiatric Association, Washington, DC
American Psychiatric Association (1994) DSM-IV. American Psychiatric Association, Washington, DC
American Psychiatric Association (2013) DSM-5. American Psychiatric Association, Washington, DC
Arildskov TW, Sonuga-Barke EJS, Thomsen PH, Virring A, and Ostergaard SD (2021) How much impairment is required for AHDH? No evidence of a discrete threshold. J Child Psychol Psychiatry, in press
Arnold LE, Abikoff HB, Cantwell DP et al (1997) NIMH collaborative multimodal treatment study of children with ADHD (MTA): design, methodology, and protocol evolution. J Atten Disord 2:141–158
Arnold LE, Hodgkins P, Caci H, Kahle J, Young S (2015a) Effect of treatment modality in long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review. PLoS One 10:1–19
Arnold LE, Hodgkins O, Kahle J, Madhoo M, Kewley G (2015b) Long-term outcomes of ADHD: academic achievement and performance. J Atten Disord X:1–10
Asherson P, Buitelaar J, Faraone SV, Rohde LA (2016) Adult attention-deficit/hyperactivity disorder: key conceptual issues. Lancet 3:568–578
Atzori P, Usala T, Carucci S, Danjou F, Zuddas A (2009) Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J Child Adolesc Psychopharmacol 19:673–681
Baader A, Kiani B, Brunkhorst-Kanaan N, Kittel-Schneider S, Reif A, Grimm O (2021) A within-sample comparison of two innovative neuropsychological tests for assessing ADHD. Brain Sci 11:36
Barkley RA (2015) Emotional dysregulation is a core component of ADHD. In: Barkley RA (ed) Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. The Guilford Press, pp 81–115
Barkley RA, Matza L, Jensen P, Schor N, Katz J, Alpern I, Tomar E, Wizniter M, Bajnrauch H, Johnson T, Gautheir B, Gower-Getz A, Nadeau K, Tuckman A, Keepnews K, Hughes R, Cattol R (2019) The adverse health outcomes, economic burden, and public health implications of unmanaged attention deficit hyperactivity disorder (ADHD): a call to action to improve the quality of life and life expectancy of people with ADHD. ADHD Public Health Summit, Washington DC
Becker SP (2020) Systematic review: assessment of sluggish cognitive tempo over the past decade. J Am Acad Child Adolesc Psychiatry 6:690–709
Becker SP, Leopold DR, Burns L, Jarrett MA, Langberg JM, Marshall SA, McBurnett K, Waschbusch DA, Willcutt EG (2016) The internal, external, and diagnostic validity of sluggish cognitive tempo: a meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry 55:163–178
Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M et al (2010) A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyper- activity disorder. J Clin Psychopharmacol 30:549–553
Biederman J, Fried R, DiSalvo B, Pulli A, Woodworth KY, Biederman I, Faraone SV, Perlis RH (2019) Evidence of low adherence to stimulant medication among children and youths with ADHD: an electronic health records study. Psychiatr Serv 70:874–880
Bishop D, Rutter M (2008) Neurodevelopmental disorders: conceptual issues. In: Rutter M, Bishop DVM, Pine DS, Scott S, Stevenson J, Taylor E, Thapar A (eds) Rutter’s child and adolescent psychiatry. Blackwell Publishing, Ltd, London
Boland H, DiSalvo M, Fried R, Woodworth KY, Wilens T, Faraone SV, Biederman J (2020) A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psychiatr Res 123:21–30
Bonvicini C, Cortese S, Maj C, Baune BT, Faraone SV, Scassellati C (2020) DRD4 48 bp multiallelic variants as age-population-specific biomarkers in attention-deficit/hyperactivity disorder. Transl Psychiatry 10:70–xx
Brickell I, Burton C, Mota NR, Martin J (2021) Insights into attention-deficit/hyperactivity disorder from recent genetic studies. Psychol Med:1–13
Buitelaar JK, Sobanski E, Stieglitz R, Dejonckheere J, Waechter S, Schauble B (2012) Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate. J Clin Psychiatry 73:1097–1102
Bunford N, Evans SW, Wymbs F (2015) ADHD and emotion dysregulation among children and adolescents. Clin Child Fam Psychol Rev 18:185–217
Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, Munafo MR (2013) Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 14:365–376
Campbell D, Kenny DA (2000) A primer on regression artifacts. Guildford Press, New York
Castellanos FX, Kelly C, Milham MP (2009) The restless brain: attention-deficit hyperactivity disorder, resting-state functional connectivity, and intrasubject variability. Can J Psychiatr 54:665–672
Caye A, Spadini AV, Karam RG et al (2016) Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis. Eur Child Adolesc Psychiatry 25:1151–1159
Chang Z, Ghirardi L, Quinn PD, Asherson P, D’Onofrio BM, Larsson H (2019) Risks and benefits of attention-deficit/hyperactivity disorder medication on Behavioral and neuropsychiatric outcomes: a qualitative review of Pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry 86(5):335–343
Charach A, Ickowicz A, Schachar R (2004) Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 43:559–567
Chen H, Cohen P, Chen S (2010) How big is a big odds ratio? Interpreting the magnitude of odds ratios in epidemiological studies. Commun Stat Simul Comput 39:1–14
Chen X, Lu B, Yan CG (2018) Reproducibility of R-fMRI metrics on the impact of different strategies for multiple comparison correction and sample sizes. Hum Brain Mapp 39:300–318
Cherkasova MV, Roy A, Molina BSG, Scott G, Weiss G, Barkley RA, Biederman J, Uchida M, Hinshaw SP, Owens EB, Hechtman L (2022) Review: adult outcome as seen through controlled prospective follow-up studies of children with attention-deficit/hyperactivity disorder followed into adulthood. J Am Acad Child Adolesc Psychiatry 61:378–391
Clark LA, Cuthbert B, Lewis-Fernandez R, Narrow WE, Reed GM (2017) Three approaches to understanding and classifying mental disorder: ICD-11, DSM-5, and the National Institute of Mental Health’s research domain criteria (RdoC). Psychol Sci Public Interest 18:72–145
Coghill D, Seth S (2015) Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD clinical care pathway. Child Adolesc Psychiatry Ment Health 9:52–5x
Cooper M, Hammerton G, Collishaw S, Langley K, Thapar A, Dalsgaard S, Stergiakouli E, Tilling K, Smith GD, Maughan B, O’Donovan M, Thapar A, Riglin L (2018) Investigating late-onset ADHD: a population cohort investigation. J Child Psychol Psychiatry 59:1105–1113
Cortese S, Adamo N, del Glovane C, Mahr-Jensen C, Mayes A, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonhoff E, Zuddas A, Barbui C, Purgato M, Steinhausen H-C, Shokraneh F, Xia J, Cipriani A (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5:727–738
Cortese S, Swanson JM, Coghill D (2020) Debate: are stimulant medications for attention-deficit/hyperactivity disorder effective in the long term? J Am Acad Child Adolesc Psychiatry 58:936–139
Currie J, Stablie M, Jones L (2014) Do stimulant medications improve educational and behavioral outcomes for children with ADHD? J Health Econ 37:58–69
Dalrymple RA, Maxwell LM, Russell S, Duthie J (2020) NICE guideline review: attention deficit hyperactivity disorder: diagnosis and management (NG87). Arch Dis Child Educ Pract Ed 105(5):289–293
Dalsgaard S, Skyt H, Simonsen M (2014) Consequences of ADHD medication use for children ’s outcomes. J Health Econ 37:137–151
Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E et al (2019) Discovery of the first genome-wide significant risk loci for attention-deficit/hyperactivity disorder. Nat Genet 51:63–75
Dopfner M, Breuer D, Wille N, Erhart M, Ravens-Sieberer U, the Bella Study Group (2008) How often do children meet ICD-10/DSM-IV criteria for attention deficit/hyperactivity disorder and hyperkinetic disorder? Parent-based prevalence rates in a national sample – results of the BELLA study. Eur Child Adolesc Psychiatry 17(Supplement 1):59–70
Eklund A, Nichols TE, Knutsson H (2016) Cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates. Proc Natl Acad Sci U S A 113:7900–7905
Fair DA, Bathula D, Nikolas MA, Nigg JT (2012) Distinct neuropsychological subgroups in typically developing youth inform heterogeneity in children with ADHD. Proc Natl Acad Sci U S A 109:6769–6774
Falissard B (2021) Did we take the right train in promoting the concept of “Neurodevelopmental disorders”? Eur Child Adolesc Psychiatry 30:179–181
Faltinsen EG, Gluud C, Simonsen E, Zwi M, Storebo OJ (2018) Unbalanced risk-benefit analysis of ADHD drugs. Lancet 5:870
Faraone SV (2008) Interpreting estimates of treatment effects. P&T 33:700–711
Faraone SV, Larsson H (2019) Genetics of attention deficit hyperactivity disorder. Mol Psychiatry 24:562–575
Faraone SV, Rostain AL, Blader J, Busch B, Childress AC, Connor DF, Newcorn JH (2019) Practitioner review: emotional dysregulation in attention-deficit/hyperactivity disorder–implications for clinical recognition and intervention. J Child Psychol Psychiatry 60:133–150
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA et al (2021) The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev 128:789–818
First MB, Gaebel W, Maj M, Stein DJ, Kogan CS, Saunders JB, Poznyak VB, Gureje O, Lewis-Fernandez R, Maercker A, Brewin CR, Cloitre M, Claudino A, Pike KM, Baird G, Skuse D, Krueger RB, Briken P, Burke JD, Lochman JE, Evans SC, Woods DW, Reed GM (2021) An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5. World Psychiatry 20:34–51
Fredriksen M, Halmøy A, Faraone SV, Haavik J (2013), Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. European Neuropsychopharmacology 23:508–527
Friedman LM, Furberg CD, DeMets DL (2010) Fundamental of clinical trials, 4th edn. New York, Springer
Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U (2012) Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry 2012;169:264–272
Gajria K, Mei L, Sikirica V, Greven P, Zhong Y, Qin P, Xie J (2014) Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review. Neuropsychiatr Dis Treat 10:1543–1569
Gao, Y., Shuai, D., Bu, X., Hu, X., Tang, S., Zhang, L., . . . Huang, X. (2019). Impairments of large-scale functional networks in attention-deficit/hyperactivity disorder: a meta-analysis of resting-state functional connectivity. Psychol Med, 49: 2475-2485
Gillberg C, Melander H, vonKnorring AL, Janols LO, Thernlund G, Hagglof B, Eidevall-L GP, Kopp S (1997) Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. Arch Gen Psychiatry 54:857–864
Grady D, Moyzis R, Swanson JM (2005) Molecular genetics and attention in ADHD. Clin Neurosci Res 5:265–272
Graziano PA, Garcia A (2016) Attention-deficit hyperactivity disorder and children’s emotion dysregulation: a meta-analysis. Clinical Psychol Rev 46:106–123
Hall CL, Valentine AZ, Walker GM, Ball HM, Cogger H, Daley D et al (2017) Study of user experience of an objective test (Qb Test) to aid ADHD assessment and medication management: a multi-methods approach. BMC Psychiatry 17:1–12
Hechtman L (2006) Long-term treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Psychiatry Rep 8:398–408
Hernan MA (2010) The hazards of hazard ratios. Epidemiology 21:13–15
Hoffman H (1848) Der Struwwelpeter oder lustige geschichten und drollige bilder: fur kinder von 3-6 jahren. Frankfurt am Main, Literarische (J. Rutten)
Hollis C, Hall CL, James B, Boadu J, Groom MJ, Brown N, Kaylor-Hughes C, Moldavsky M, Valentine AZ, Walker GM, Daley D, Sayal K, Morriss R, the AQUA Trial Group (2018) The impact of the test of attention and activity (QbTest) on diagnostic decision-making in children and young people with suspected attention deficit hyperactivity disorder: single-blind controlled trial. J Child Psychol Psychiatry 59:1298–1308
Hoogman, M., Bralten, J., Hibar, DP, Mennes, M., Zwiers, MP, Schweren, LSJ, . . . Franke B (2017). Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. Lancet Psychiatry, 4: 310-319
Hoogman, M., Muetzel, R., Guimaraes, J. P., Shumskaya, E., Mennes, M., Zwiers, M. P., . . . Franke, B. (2019). Brain imaging of the cortex in ADHD: a coordinated analysis of large-scale clinical and population-based samples. Am J Psychiatry, 176: 531-542
Huss M, Duhan P, Gandhi P, Chen CW, Spannhuth C, Kumar V (2017) Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity. Neuropsychiatr Dis Treat 13:1741–1751
Ilbegi S, Buitelaar JK, Hoekstra PJ, Hartman CA, Franke B, Faraone SV et al (2021) Neurocognitive markers of late-onset ADHD: a 6-year longitudinal study. J Child Psychol Psychiatry 62:244–252
Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, Sanislow C, Wang P (2010 Jul) Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 167(7):748–751
Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, March JS, Arnold LE, Cantwell DP, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Pelham WE, Severe JB, Swanson JM, Wells KC, Wigal T, Vitiello B (2001) ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 40:147–158
Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, Hechtman L, Hinshaw SP, Pelham WE, Wells KC, Conners CK, Elliott GR, Epstein JN, Hoza B, March JS, Molina BS, Newcorn JH, Severe JB, Wigal T, Gibbons RD, Hur K (2007) 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 46:989–1002
Kazda KM, Walters RK, Demontis D, Stein JL, Hibar HH, Bralten J, Mota NR, Schchar R, Sonuga-Barke E, Mattenisen M, Neale BM, Thompson PM, Medland SE, Borglim AD, Faraone SV, Arias-Zasquez, and Franke B. (2021) Overdiagnosis of attention-deficit/hyperactivity disorder in. Children and adolescents: a scoping review. Am J Psychiatr 176:228–238
Klein M, Walters RK, Demontis D, Stein JL, Hibar HH, Bralten J, Mota NR, Schachar R, Sonuga-Barke E, Mattheisen M, Neale BM, Thompson PM, Medland SE, Borglum AD, Faraone SV, Arias-Vasquez A, Franke B (2019) Genetic markers of ADHD-related variations in intracranial volume. Am J Psychiatr 176:228–238
Kofler MJ, Irwin LN, Sarver DE, Fosco WD, Miller CE, Spiegel JA, Becker SP (2019) What cognitive processes are “sluggish” in sluggish cognitive tempo? J Consult Clin Psychol 87:1030–1042
Kortekaas-Rijlaarsdam AF, Luman M, Sonuga-barke E, Oosterlaan J (2018) Does methylphenidate improve academic performance? A systematic review and meta-analysis. Eur Child Adolesc Psychiatry 1(0123456789)
Koziol LF, Stevens MC (2012) Neuropsychological assessment and the paradox of ADHD. Appl Neuropsychol Child 1:79–89
Kraemer HC (2009) Events per person-time (incidence rate): a misleading statistic? Stat Med 28:1028–1039
Kraemer HC, Kupfer DJ (2006) Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 59:990–996
Kuntsi J, Wood AC, Johnson KA, Andreou P, Arias-Vasquez A, Buitelaar JK et al (2010) Separation of cognitive impairments in attention-deficit/hyperactivity disorder into 2 familial factors. Arch Gen Psychiatry 67:1159–1166
Lam AP, Matthies S, Graf E, Colla M, Jacob C, Sobanski E, Alm B, Rosler M, Retz W, Retz-Junginger P, Kis B, Abdel-Hamid M, Muller HHO, Lucke C, Huss M, Jans T, Berger M, van Elst LT, Phillipsen A (2019) Long-term effects of multimodal treatment on adult attention-deficit/hyperactivity disorder symptoms: follow-up analysis of the COMPAS trial. JAMA Netw Open 2:1–17
Lichtenstein P, Halldner L, Zetterqvist J, Sjolander A, Serlachius E, Fazel S, Langstrom N, Larsson H (2012) Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 367:2006–2014
Loe IM, Feldman H (2007) Academic and educational outcomes of children with ADHD. J Pediatr Psychol 32:643–654
Lohr WD, Wanta JW, Baker M, Grudnikoff E, Morgan W, Chhabra D, Lee T (2021) Intentional discontinuation of psychostimulants used to treat ADHD in youth: a review and analysis. Front Psych 12:1–14
Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TFC, McCarroll SA, Visscher PM (2009) Finding the missing heritability of complex diseases. Nature 461:747–753
Marcus SC, Durkin M (2011) Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 50:480–489
Martel MM (2009) Research Review: A new perspective on attention-deficit/hyperactivity disorder: emotion dysregulation and trait models. J Child Psychol Psychiatry 50:1042–1051
Matthijssen AFM, Dietrich A, Bierens M, Deters RK, van de Loo-Neus GHH, van den Hoofdakker BJ, Buitelaar JK, Hoekstra PJ (2019) Continued benefits of methylphenidate in ADHD after 2 years in clinical practice: a randomized placebo-controlled discontinuation study. Am J Psychiatr 176:754–762
McCarthy S, Wilton L, Murray ML et al (2012) The epidemiology of pharmacological treated ADHD in children, adolescents, and adults in UK primary care. BMC Pediatr 12:1–11
Menon V (2011) Large-scale brain networks and psychopathology: a unifying triple network model. Trends Cogn Sci 15:483–506
Miller AR, Lalonde CE, McGrail KM (2004) Children’s persistence with methylphenidate therapy: a population-based study. Can J Psychiatr 49:761–768
Moffitt TE, Houts R, Asherson P et al (2015) Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry 172:967–977
Molina BSG, Swanson JM (2020) Why are long-term benefits of stimulant medication so difficult to detect? ADHD Report 28:1–7
Molina BSG, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, Epstein JN, Hoza B, Hechtman L, Abikoff HB, Elliott GR, Greenhill LL, Newcorn JH, Wells KC, Wigal T, Gibbons RD, Hur K, Houck PR (2009) The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 48:484–500
Mooney MA, Bhatt P, Hermosillo RJM, Ryabinin P, Nikolas M, Faraone SV, Fair DA, Wilmot B, Nigg JT (2021) Smaller total brain volume but not subcortical structure volume related to common genetic risk for ADHD. Psychol Med X:1–10
MTA Cooperative Group (1999a) A 14-month randomized clinical trial of treatment strategies for ADHD. Arch Gen Psychiatry 56:1073–1086
MTA Cooperative Group (1999b). Moderators and Mediators of treatment response for children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1088–1096
MTA Cooperative Group (2004) 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder (ADHD): the NIMH MTA follow-up. Pediatrics 113:754–761
Myer NM, Boland JR, Faraone SV (2018) Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry 23:1929–1936
National Research Council (1989) Research on children and adolescents with mental, behavioral, and developmental disorders: mobilizing a national initiative. The National Academies Press, Washington, DC
Nigg JT, Karalunas SL, Gustafsson HC, Bhatt P, Ryabinin P, Mooney MA et al (2020a) Evaluating chronic emotional dysregulation and irritability in relation to ADHD and depression genetic risk in children with ADHD. J Child Psychol Psychiatry 61:205–214
Nigg JT, Karalunas SL, Feczko E, Fair DA (2020b) Toward a revised nosology for ADHD heterogeneity. Biol Psychiatry Cogn Neurosci Neuroimaging 5:726–737
NIH (1992) NIMH-92-03, cooperative agreement for a multi-site treatment study of attention-deficit hyperactivity disorder/attention deficit disorder. NIH Guide 21:1–25
Nikolaidis A, Gray JR (2009) ADHD and the DRD4 exon III 7-repeat polymorphism: an international meta-analysis. Soc Cogn Affect Neurosci 5:188–193
Norbury CF, Sparks A (2013) Difference or disorder? Cultural issues in understanding neurodevelopmental disorders. Dev Psychol 49:45
Olivier J, May WL, Bell ML (2017) Relative effect sizes for measures of risk. Commun Statist Theory Methods 46:6774–6781
Owens, M. M., Allgaier, N., Hahn, S., Yuan, D., Albaugh, M., Adise, S., . . . Garavan, H. (2021). Multimethod investigation of the neurobiological basis of ADHD symptomatology in children aged 9-10: baseline data from the ABCD study. Transl Psychiatry, 11: 64
Pelham WE III, Page TF, Altszuler AR, Gnagy EM, Molina BSG, Pelham WE Jr (2020) The long-term financial outcome of children diagnosed with ADHD. J Consult Clin Psychol 88:160–171
Pereira-Sanchez V, Castellanos FX (2021) Neuroimaging in attention-deficit/hyperactivity disorder. Curr Opin Psychiatry 34:105–111
Philipsen A, Thomas J, Graf E, Matthies S, Borel P, Colla M, Gentschow L, Langner D, Jacob C, Gross-Lesch S, Sobanski E, Alm B, Schumacher-Stien M, Roesler M, Retz W, Retz-Junginger P, Kis B, Adbel-Hamid M, Heinrich V, Huss M, Kornmann C, Burger A, Perlov E, Ihorst G, Schander M, Berger M, van Elst LT, for the comparison methylphenidate and psychotherapy in adult ADHD study (COMPAS) consortium (2015) Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry 72:1199–1210
Polanczyk GV, Willcutt EG, Salum GA et al (2014) ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 43:434–442
Posner J, Polanczyk GV, Sonuga-Barke E (2020) Attention-deficit hyperactivity disorder. Lancet 395:450–462
Postema, M. C., Hoogman, M., Ambrosino, S., Asherson, P., Banaschewski, T., Bandeira, C. E., . . . Francks, C. (2021). Analysis of structural brain asymmetries in attention-deficit/hyperactivity disorder in 39 datasets. J Child Psychol Psychiatry 62(10):1202-1219
Poulton AS, Patterson R (2020) Stimulant prescribing for attention deficit hyperactivity disorder (ADHD): what guides clinicians in their choice of an upper limit for dose titration? Austr Psychiatry:1–5
Qureshi MNI, Oh J, Min B, Jo HJ, Lee B (2017) Multi-modal, multi-measure, and multi-class discrimination of ADHD with hierarchical feature extraction and extreme learning machine using structural and functional brain MRI. Front Hum Neurosci 11:157
Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, Buchnell G, Crystal S, Furu K, Yang YHK, Karsstad O, Kieler H, Kubota K, Lai ECC, Martikainen J, Maura G, Moore N, Montero D, Nakamura H, Pate A, Pottegard A, Pratt NL, Roughead EE, Saint-Gerans DM, Sturmer T, Su CC, Zoega H, Sturkenbroom MCJM, Chan EW, Coghill D, Ip P, Wong ICK (2019) Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry 5:824–835
Reed GM, First MB, Kogan CS, Hyman SE, Gureje O, Gaebel W, Maj M, Stein DJ, Maercker A, Tyer P, Claudino A, Garralda E, Salvador-Carulla L, Ray R, Saunders JB, Dua T, Poznyak V, Medina-Mora E, Pike KM, Ayuso-Mateos JL, Kanba S, Keeeley JW, Khoury B, Krasnov VN, Kulygina M, Lovell AM, Mari JDJ, Maruta T, Matsumoto C, Rebello TJ, Roberts MC, Robles R, Sharan P, Zhao M, Jablensky A, Udomratn P, Rahimi-Movaghar A, PA TR, Bahrer-Kohler S, Watts AD, Saxena S (2019) Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry 18:3–19
Ribeiro JP, Arthur EJ, Glud C, Simonsen E, Storebo OJ (2021) Does methylphenidate work in children and adolescents with attention deficit hyperactivity disorder? Pediatr Rep 13:434–443
Rommelse N, Bunte T, Matthys W, Anderson E, Buitelaar J, Wakschlag L (2015) Contextual variability of ADHD symptoms: embracement not erasement of a key moderating factor [editorial]. Eur Child Adolesc Psychiatry 24:1–4
Rommelse N, Luman M, Kievit R (2020) Slow processing speed: a cross-disorder phenomenon with significant clinical value, and in need of further methodological scrutiny. Eur Child Adolesc Psychiatry 29:1325–1327
Rutter M, Bishop DVM, Pine DS, Scottt S, Stevenson J, Taylor E, Thapar A (2008) Rutter’s child and adolescent psychiatry. Blackwell Publishing, Ltd, London
Saccone SF, Bierut LJ, Chesler EJ, Kalivas PW, Lerman C, Saccone NL, Uhl GR, Li CY, Philip VM, Edenberg HJ, Sherry ST, Feolo M, Moyzis RK, Rutter JL (2009) Supplementing high-density SNP microarrays for additional coverage of disease-related genes: addiction as a paradigm. PLoS One 4:e5225–eexxx
Sackett D, Deeks J, Altman D (1966) Down with odds ratios! Evidence-based Medicine 1:164–166
Safer DJ (2016) Recent trends in stimulant usage. J Atten Disord 20:471–477
Samea F, Soluki S, Nejati V, Zarei M, Cortese S, Eickhoff SB, Tahmasian M, Eickhoff CR (2019) Brain alterations in children/adolescents with ADHD revisited: a neuroimaging meta-analysis of 96 structural and functional studies. Neurosci Biobehav Rev 100:1–8
Santosh PM, Taylor E, Swanson J, Wigal T, Chuang S, Davies M, Greenhill L, Newcorn J, Arnold LE, Jensen P, Vitiello B, Elliott G, Hinshaw S, Hechtman L, Abikoff A, Pelham W, Hoza B, Molina B, Epstein J, Posner M (2005) Refining the diagnoses of inattention and overactivity syndromes: a reanalysis of the Multimodal Treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder. Clin Neurosci Res 5:307–314
Scheffler RM, Hinshaw SP, Modrek S, Levine P (2005) The global market for ADHD-medications. Health Aff 26:450–457
Shaw M, Caci H, Kahle J, Woods AG, Arnold LE (2012) A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder. BMC Med 10:99
Shaw P, Stringaris A, Nigg J, Leibenluft E (2014) Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatr 171:276–293
Sherman M, Hertzig ME (1991) Prescribing practices of Ritalin: The Suffolk County, New York Study. In: Greenhill LL, Osman BB (ed) Ritalin: theory and patient management. Mary Ann Liebert, Inc., New York City
Sibley MH, Swanson JM, Arnold LE, Hechtman LT, Owens EB, Stehli A, Abikoff H, Hinshaw SP, BSG M, Mitchell JT, Jensen PS, Howard AL, Lakes KD, Pelham WE, MTA Cooperative Group (2017) Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity. J Child Psychol Psychiatry 58:655–662
Sibley MH, Rohde LA, Swanson JM, Hechtman LT, Molina B, Mitchell JT, Arnold LE, Caye A, Kennedy TM, Roy A, Stehli A, Multimodal Treatment Study of Children with ADHD (MTA) Cooperative Group (2018) Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. Am J Psychiatr 175:140–149
Sibley MH, Arnold AL, Swanson JM et al (2021) Variable patterns of remission from ADHD in the multimodal treatment study of ADHD. Online early
Sonuga-Barke EJ, Castellanos FX (2007) Spontaneous attentional fluctuations in impaired states and pathological conditions: a neurobiological hypothesis. Neurosci Biobehav Rev 31:977–986
Sonuga-Barke EJS, Brandeis DF, Cortese S, Daley D, Ferrin M, Holtmann M, Stevenson J, Danckaerts M, van der Oord S, Dopfner M, Dittmann RW, Simonoff E, Zuddas A, Banaschewski T, Buitelaar J, Coghill D (2013) Non-pharmacological interventions for ADHD: systematic review and meta-analysis of randomized controlled trials of dietary and psychological treatments. Am J Psychiatr 170:275–289
Stein DJ, Szatman P, Gaeber W, Berk M, Vieta E, Maj M, de Vries YA, Roest AM, de Jonge P, Maerder A, Brewin CR, Pike KM, Grilo CM, Fineberg NA, Briken P, Cohen-Kettenis PT, Reed GM (2020) Mental, behavioral and neurodevelopmental disorders in the ICD-11: an international perspective on key changes and controversies. BMC Med 18:21–45
Still GF (1902) Some abnormal psychical conditions in children. Lancet 1:1008–1012
Storebo OJ, Ramstad E, Krough HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Ramussen K, Gauci D, Zwi M, Kirubakaran R, Forsbol B, Simonsen E, Gluud C (2015) Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review). Issue 11
Sutcubasi B, Metin B, Kurban MK et al (2020) Resting-state network dysconnectivity in ADHD: a system-neuroscience-based meta-analysis. World J Biol Psychiatry 21:662–672
Swanson J, Lerner M, Wigal T, Steinhoff K, Greenhill L, Posner K, Freid J, Wigal S (2002) The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord 6:S73–S88
Swanson JM (2018) Risk of bias and quality of evidence for treatment of ADHD with stimulant medication. Clin Pharmacol Ther 104:638–6xx
Swanson JM, Volkow ND (2009) Psychopharmacology: concepts and opinions about the use of stimulant medications. J Child Psychol Psychiatry 50:180–193
Swanson JM, McBurnett K, Wigal T, Pfiffner LJ, Lerner MA, Williams L, Christian DL, Tamm L, Wilcutt E, Crowley K, Clevenger W, Khouzam N, Woo C, Crinella FM, Fisher TD (1993) Effect of stimulant medication on children with attention deficit disorder: a “Review of Reviews”. Except Child 60:154–162
Swanson JM, Lerner MA, Williams L (1995) More frequent diagnosis of ADHD. N Engl J Med 333:944
Swanson JM, Sergeant J, Taylor E, Sonuga-Barke EJS, Jensen PS, Cantwell DP (1998) Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 351:429–433
Swanson JM, Flodman P, Kennedy J, Spence MA, Moyzis R, Schuck S, Murias M, Moriarity J, Barr C, Smith M, Posner M (2000) Dopamine genes and ADHD. Neurosc Biobehav Rev 24:21–25
Swanson JM, Arnold LE, Hechtman L, Molina B, Hinshaw S, Vitiello B, Jensen P, Steinhoff K, Lerner M, Greenhill L, Abikoff H, Wells K (2008) Wigal T for the MTA cooperative group. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the multimodal treatment study of children with ADHD (MTA). J Atten Disord 12:4–43
Swanson JM, Sergeant JA, Taylor EA, Sonuga-Barke EJS, Jensen PS, Castellanos FX (2016) Chapter 142: attention deficit hyperactivity disorder. In: Pfaff DW, Volkow ND (eds) Neuroscience in the 21st century. Springer, New York
Swanson JM, Arnold LE, Molina B, Sibley MH, Hechtman LT, Hinshaw SP, Abikoff H, Stehli A, Owens ER, Mitchell JT, Nichols Q, Howard A, Greenhill LL, Hoza B, Newcorn J, Jensen P, Vitiello B, Wigal T, Epstein J, Tamm L, Lakes KD, Waxmonksy J, Lerner M, Etcovitch J, Murry D, Muenke M, Acosta M, Arcos-Burgos M, Pelham WE, Kraemer H for the MTA Group (2017) Outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry 58:663–678
Swanson JM, Arnold E, Jensen PS, Hinshaw SP, Hechtman LT, Pelham WE, Greenhill LL, Conners CK, Kraemer HC, Wigal T, Vitiello B, Elliott GR, Abikoff HB, Hoza B, Newcorn JH, Owens EB, Waxmonsky J, Murray DW, Sibley MH, Mitchell JT, Roy A, Stehli A for the MTA Group (2018) Long-term outcome in the multimodal treatment study of children with ADHD (the MTA): from beginning to end. In: Banaschewski T, Coghill D, Zuddas A (eds) Chapter 34, Oxford textbook of attention deficit hyperactivity disorder. Oxford University Press, Oxford
Taylor E (2019) ADHD medication in the longer term. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie X:1–5
Thapar A, Cooper M (2016) Attention deficit hyperactivity disorder. Lancet 387:1240–1250
Thiruchelvam D, Charach A, Schachar RJ (2001) Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry 40:922–928
Thompson, P. M., Stein, J. L., Medland, S. E., Hibar, D. P., Vasquez, A. A., Renteria, M. E., . . . Drevets, W. (2014). The ENIGMA consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav, 8: 153-182
van Dessel J, Sonuga-Barke E, Mies G, et al (2018) Delay aver- sion in attention deficit/hyperactivity disorder is mediated by amygdala and prefrontal cortex hyper-activation. J Child Psychol Psychiatry Allied Discip 59:888–899
Volkow ND, Insel TR (2003) What are the long-term effects of methylphenidate treatment? Biol Psychiatry 54:1307–1309
Volkow ND, Swanson JM (2008) Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Am J Psychiatry 165:1–2
Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, Fowler JS, Zhu W, Logan J, Ma Y, Pradhan K, Wong C, Swanson JM (2009) Evaluating dopamine reward pathways in ADHD. JAMA 302:1084–1091
Vos M, Rommelse NN, Franke B, Oosterlaan J, Heslenfeld DJ, Hoekstra PJ, Klein M, Faraone SV, Buitelaar JK, Hartman CA (2021) Characterizing the heterogeneous course of inattention and hyperactivity-impulsivity from childhood to young adulthood. Eur Child Adolesc Psychiatry:1–11
Wakeman DG, Henson RN (2015) A multi-subject, multi-modal human neuroimaging dataset. Sci Data 2(1):150001
WHO (1949) International statistical classification of diseases, injuries, and causes of death, Sixth Revision. World Health Organization, Geneva
WHO (1966) The ICD-8 classification of mental and behavioral disorders. WHO, Geneva
WHO (1993) The ICD-10 classification of mental and behavioral disorders. WHO, Geneva
WHO (2018) The ICD-11 classification of mental and behavioral disorders. WHO, Geneva
Willcutt EG, Doyle AE, Nigg JT et al (2005) Validity of the executive function theory of ADHD: a meat-analytic review. Biol Psychiatry 57:1336–1346
Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR, Lehman CU, Lessin HR, Okechukwu K, Pierce KL, Winner JD (2019) Zurhellen W for the subcommittee on children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 144:1–25
Wong CK, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoya R, Hollis C, McCarthy S, Murray M, Planner C, Potts L, Sayal K, Taylor E (2009) Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY) – a pharmacoepidemiological and qualitative study. Health Technol Assess 13:11–54
World Health Organization (2019) The selection and use of essential medicines. The 21st WHO model list of essential medicines and the 7th WHO model list of essential medicines for children. Section 24: medicines for mental and behavioural disorders. Methylphenidate—Addition—EML and EMLc. Available online: https://www.who.int/medicines/publications/essentialmedicines/en/
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendix A
Appendix A
aWhat is the current controversy about categorical diagnosis? Even though the categorical approach was retained in DSM-5 and ICD-11 and the criteria and label for ADHD converged (see First et al. 2021), the controversy about the dimensional approach has continued. For example, Thapar and Cooper (2016) suggested “for clinical practice, there is need for strict categories, otherwise diagnostic spread would become at best unhelpful and at worst risky and unethical [and] application of evidence-based treatments would become impossible.” The proposed categories may serve as a vehicle for the development of evidence-based clinical practices, despite strong evidence from research that ADHD is dimensional. The general approach applied to revise diagnostic categories in ICD-11 (including the transition from the HKD to the ADHD diagnosis) has been described as “incorporation of dimensional approaches within the context of an explicitly categorical system” (see Reed et al. 2019), but the categorical-dimensional debate (including consideration of the RDoC approach) has not been resolved (see Clark et al. 2017).
bAre fundamental statistical assumptions met regarding severity and impairment? Two recent collaborative studies (including some authors of this chapter) addressed interesting statistical properties of measures of severity and impairment of ADHD relevant to this controversy and highlight fundamental issues. Alexander et al. (2020) applied the item-rating approach of the Strengths and Weaknesses of ADHD and Normal behavior (SWAN) rating scale to most psychiatric disorders of childhood and created the Extended-SWAN. This avoids categorical truncation of ratings of possible strengths (at the item level) and allows ratings across the full range of underlying behavior, which provides population norms that have near-normal distributions instead of highly skewed distributions. Arildskov et al. (2021) questioned the traditional categorical definition of impairment (based on the assumption of a qualitative threshold for symptom severity where impairment would suddenly increase). This study described a linear relationship between severity of impairment and severity of ADHD symptoms, providing no evidence for a discrete, nonarbitrary symptom severity threshold that is associated with a marked step increase in impairment. This led to a conclusion that specification of a symptom-count cutoff (as in DSM-5) creates a challenge (“clinicians need to make a categorical decision while no such categorical threshold seems to exist”).
cWhat is the new superordinate classification of “Neurodevelopmental Disorder?” In both DSM-5 and ICD-11, ADHD is classified as a neurodevelopmental disorder (NDD), which replaced the previous superordinate classification as a “disruptive behavior disorder” (in DSM-IV) and “behavioral and emotional disorders with onset in childhood or adolescence” (in ICD-10). According to Falissard (2021), the term NDD has origins from the field of neurology (see where it was used to describe disorders such as epilepsy, cerebral palsy and mental retardation, with poor prognosis and limited association with psychosocial factors), and the current concept of NDD in psychiatry became widely accepted for use in child psychiatry after Bishop and Rutter et al. (2008) proposed a conceptual definition in a textbook based on specific characteristics (early onset, delayed CNS maturation, and steady course). The NDD concept may become problematic in the future for the superordinate classification of ADHD in DSM-5 and ICD-11, since the early onset requirement for ADHD was relaxed and some even suggest should be eliminated (see Asherson et al. 2019), the NDD category was broadened and some suggest this may undermine clinical utility regarding treatment and prognosis (see Szatmari in Stein et al. 2020), and “presentations” of ADHD can change and symptoms may dissipate or wax and wane over time (see Moffitt et al. 2015; Sibley et al. 2021). These issues may question the validity of superordinate classification of ADHD as a neurodevelopmental rather than behavioral disorder (see Norbury and Sparks 2013).
dIs “Emotional Dysregulation” central to ADHD? Some investigators suggest ADHD should be conceptualized as a disorder of self-regulation, which encompasses not only deficits in regulation of attention, activity, and impulses but also emotions. Emotional dysregulation may not be properly reflected in current diagnostic criteria. It has been characterized by many investigators as (a) “high negative and positive emotionality [and] deficient control processes” (Martel 2009), (b) “irritability and mood lability” (Shaw et al. 2014), (c) “a deficiency [in] self-regulation of frustration, impatience, and anger” (Barkley 2015), (d) “difficulties with managing anger, frustration, and other negative emotions [and] positive emotions” (Bunford et al. 2015), (e) “reactive to stressful and/or frustrating situations” (Graziano and Garcia 2016), (f) “emotionally immature, overly exuberant, rambunctious, low tolerance for anger and frustration” (Bunford et al. 2015), and (e) “approach-related dysregulation and surgency-sensation seeking” that extends beyond irritability (Nigg et al., 2020a). These characterizations support a broad conceptualization of ADHD as a disorder of self-regulation, involving not only regulation of cognitive processes but also of emotions (Faraone et al. 2019; Nigg et al. 2020a, b. However, emotional dysregulation may occur in many mental disorders and thus be considered a transdiagnostic correlate, and specific aspects implicated in ADHD need to be isolated (Aldao et al. 2016). This is not a recent addition. In our previous 1998 seminar (part of the centennial celebration of the Lancet and some classic articles published during the twentieth century), we referred to Still (1902), who in eloquent case reports included a description of some children with “morbid exaggeration of emotional excitability.”
eWhat is slow or sluggish cognitive tempo (SCT)? Some investigators suggest children with the inattentive presentation of ADHD show additional behaviors that are not captured by the diagnostic criteria for inattentiveness in DSM-5 or ICD-11, such as daydreaming, staring, mental fogginess, confusion, hypoactivity, sluggishness, slow movement, lethargy, apathy, and sleepiness (Becker et al. 2016; Becker 2020). Since the 1980s, this constellation of associated features has been described as slow or sluggish cognitive tempo (SCT), which can be reliably assessed across informants and uniquely predicts higher depressive symptoms, academic impairment, and social impairment. This may inform treatment choice and prognosis, since cases with SCT may have reduced benefit associated with treatment with stimulant medication (Becker 2020) and increased benefit associated with allowances for extra time to complete work or take tests (Kofler et al. 2019), due to a combination of weak or slow working memory capacity (requiring extra time to rearrange active contents) and average to strong inhibition systems (that terminate further input and prevent intended behaviors). This is not a recent addition, either, since it was suggested previously in the classic historical accounts of childhood mental disorders in the early twentieth century (Still 1902) and even earlier by Hoffman (1848) in a popular nineteenth century children’s book of “funny stories and whimsical pictures” that described prototype children with abnormal behaviors remarkably like symptoms of modern psychiatric disorders of childhood (e.g., “Johnny Look-in-the-Air,” with symptoms of SCT).
Rights and permissions
Copyright information
© 2022 Springer Science+Business Media, LLC, part of Springer Nature
About this entry
Cite this entry
Swanson, J.M., Rommelse, N., Cotton, J., Sonuga-Barke, E.J.S., Jensen, P.S., Castellanos, F.X. (2022). Attention-Deficit Hyperactivity Disorder. In: Pfaff, D.W., Volkow, N.D., Rubenstein, J. (eds) Neuroscience in the 21st Century. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6434-1_169-2
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6434-1_169-2
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6434-1
Online ISBN: 978-1-4614-6434-1
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences
Publish with us
Chapter history
-
Latest
Attention-Deficit Hyperactivity Disorder- Published:
- 07 September 2022
DOI: https://doi.org/10.1007/978-1-4614-6434-1_169-2
-
Original
Attention Deficit Hyperactivity Disorder- Published:
- 08 April 2016
DOI: https://doi.org/10.1007/978-1-4614-6434-1_169-1